Three Phase 3 failures in 12 months leave Arcus a company-defining PDAC readout and an unproven inflammation pivot as its remaining case

Arcus is a clinical-stage oncology company whose lead approved-stage program targets pancreatic cancer, though that drug is not yet approved.

Arcus lost its founding oncology franchise in rapid succession: domvanalimab was discontinued across NSCLC and gastric Phase 3 trials after futility, and Gilead walked away from the collaboration. The investment case now rests on quemliclustat in first-line metastatic pancreatic cancer, a disease with almost no approved second-line options, where a Phase 3 win would be transformative but a miss would leave only pre-clinical-stage inflammation programs. The deepest structural risk is that quemliclustat's PRISM-1 data arrives against a history of failed first-line PDAC combination trials, with no validated biomarker to predict responders.